Results 191 to 200 of about 36,256 (261)
Supplementary Figure S1 from Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study [PDF]
Yvette Drew, Jae‐Weon Kim, Richard T. Penson, David M. O’Malley, Christine Parkinson, Patricia Roxburgh, Ruth Plummer, Seock‐Ah Im, Martina Imbimbo, Michelle Ferguson, Ora Rosengarten, Neeltje Steeghs, Min Hwan Kim, Einav Nili Gal‐Yam, Daliah Tsoref, Jae‐Hoon Kim, Benoît You, Maja J.A. de Jonge, Roy Lalisang, Eelke Gort, Sara Bastian, Kassondra Meyer, Laura Feeney, Nigel Baker, Mei-Lin Ah-See, Susan M. Domchek, Susana Banerjee +26 moreopenalex +1 more sourceSupplementary Table S4 from A Phase II Open-Label Randomized Clinical Trial of Preoperative Durvalumab or Durvalumab plus Tremelimumab in Resectable Head and Neck Squamous Cell Carcinoma
Chang Gon Kim, Min Hee Hong, Dahee Kim, Brian Hyohyoung Lee, Hyunwook Kim, Chan‐Young Ock, Geoffrey Kelly, Yoon Ji Bang, Gamin Kim, Jung Eun Lee, Chaeyeon Kim, Se‐Heon Kim, Hyun Jun Hong, Young Min Park, Nam Suk Sim, Heejung Park, Jin Woo Park, Chang Geol Lee, Kyung Hwan Kim, Goeun Park, Inkyung Jung, Dawoon Han, Jong Hoon Kim, Junha Cha, Insuk Lee, Mingu Kang, Heon Song, Chiyoon Oum, Seulki Kim, Sukjun Kim, Yoojoo Lim, Seunghee Kim‐Schulze, Miriam Mérad, Sun Och Yoon, Hyun Je Kim, Yoon Woo Koh, Hye Ryun Kim +36 moreopenalex +1 more sourceSupplementary Figure S4 from Durvalumab ± Tremelimumab + Platinum-Etoposide in Extensive-Stage Small Cell Lung Cancer (CASPIAN): Outcomes by PD-L1 Expression and Tissue Tumor Mutational Burden [PDF]
Luis Paz‐Ares, Marina Chiara Garassino, Yuanbin Chen, Niels Reinmuth, Katsuyuki Hotta, Artem Poltoratskiy, Dmytro Trukhin, Maximilian J. Hochmair, Mustafa Özgüroğlu, Jun Ho Ji, Galina Statsenko, Nikolay Conev, Igor Bondarenko, Libor Havel, György Losonczy, Mingchao Xie, Zhongwu Lai, Nadia Godin-Heymann, Helen Mann, Haiyi Jiang, Yashaswi Shrestha, Jonathan W. Goldman +21 moreopenalex +1 more sourcePopulation Pharmacokinetics and Exposure-Response Analysis of Durvalumab in Combination with Gemcitabine and Cisplatin in Patients with Advanced Biliary Tract Cancer [PDF]
Aburough Abegesah, Do-Youn Oh, KyoungSoo Lim, Chunling Fan, Cecil Chen, Chong Ae Kim, Julie Wang, Ioannis Xynos, Magdalena Żotkiewicz, Song Ren, Alex Phipps, Megan Gibbs, Diansong Zhou +12 moreopenalex +1 more sourceTreatment outcome and safety of durvalumab after concurrent chemoradiation in very elderly patients with unresectable stage III non-small cell lung cancer. [PDF]
Transl Lung Cancer ResKim SJ, Kim NY, Chung SJ, Hyun IG, Yeo Y, Park JY, Jang SH, Kim T, Sim YS, Lee CY, Kim J. +10 moreeuropepmc +1 more sourceDurvalumab and tremelimumab in patients with advanced rare cancer: a multi-centre, non-blinded, open-label phase II basket trial
Abha A. Gupta, Anna V. Tinker, D. Jonker, Rahma Jamal, Hal Hirte, Eric Winquist, Quincy S. Chu, Christian Kollmannsberger, Ralph Wong, Thierry Alcindor, Torsten O. Nielsen, Ming‐Sound Tsao, Tricia R. Cottrell, Diane Provencher, John Hilton, Monika K. Krzyzanowska, Christine Elser, Sébastien J. Hotte, Joana Sederias, Siwei Zhang, Wei Tu, Janet Dancey +21 moreopenalex +1 more sourceAdvanced intestinal-type ampullary cancer successfully treated using combination therapy with gemcitabine, cisplatin, and durvalumab: A case report. [PDF]
SAGE Open Med Case RepHanatani JI, Kitagawa K, Asada S, Motokawa Y, Osaki Y, Iwata T, Kaji K, Mitoro A, Tsujimura M, Yoshiji H. +9 moreeuropepmc +1 more source
